IMPORTANT ACORDA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors

NEW YORK, Nov. 30, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that  a class  action  lawsuit  has  been  filed  against  Acorda  Therapeutics,  Inc. (“Acorda” or the Company”)  (NASDAQ:ACOR)  in the  United States District Court for the Southern District of New  York with a class period between April  18, 2016, and November 14, 2017, both dates inclusive.

Investors who have incurred losses in Acorda  Therapeutics,  Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If  you  have incurred losses in the shares of Acorda  Therapeutics,  Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no  later than January 17, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Acorda Therapeutics, Inc.

The field Complaint  alleges  that  throughout the  Class  Period,  Defendants  made materially false and misleading  statements regarding the Company’s  business, operational and  compliance  policies. 

Specifically, Defendants  made  false and/or misleading statements and/or failed  to disclose that: 

• tozadenant entailed significant undisclosed safety  risks;
   
• accordingly, the  Company had overstated tozadenant’s approval prospects and commercial viability;
   
• for the foregoing reasons, the Company had likewise overstated the benefits of the Biotie Acquisition; and
   
• as a result of the foregoing, Acorda’s shares traded at  artificially inflated  prices during  the Class  Period, and  class members suffered significant losses and damages.

On November 15, 2017,  Acorda  disclosed  the deaths of several patients in  the Company’s final-stage studies of tozadenant.   Acorda advised investors that it had paused  new enrollment  in the  drug’s long-term  safety studies,  pending further discussion with the independent  Data Safety Monitoring Board and  the U.S. Food and Drug Administration.

On this news, Acorda’s share price fell $11.20, or 39.72%, to close at $17.00 on November 15, 2017, a market capitalization drop of $525 million.

Wolf Haldenstein Adler Freeman & Herz  LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.